PERCEPTIVE TO MARKET VIVOMETRICS? LIFESHIRT SYSTEM
BOSTON, MA, June 13, 2003 — Perceptive Informatics, Inc. (Perceptive), a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), today announced that it has entered into an agreement to market the LifeShirt System developed by VivoMetrics.
The LifeShirt System is the first non-invasive, continuous ambulatory monitoring system that can collect data on ventilation, ECG, posture and physical activity as well as other physiological parameters and correlate them over time. It also includes a diary function to capture subjective patient experiences and validate them against objective measures.
"It is the mission of Perceptive to leverage technologies that can accelerate the clinical trial process," said Mark A. Goldberg, MD, President of Perceptive. "The ability of the LifeShirt System to provide continuous physiologic monitoring during a clinical trial, together with Perceptive’s trial management and portal solutions, will give clients visibility into the efficacy and safety profiles of their compounds."
The LifeShirt System monitors subjects’ physiologic parameters 24/7 as they go about their day, enabling them to carry out normal activities without interruption. As a result, trial researchers are able to garner more realistic data. Additionally, providing subjects with the ability to be monitored during normal activity significantly lowers the inconvenience of participation.
"Teaming with Perceptive was a natural fit for VivoMetrics," said James D. Utterback, President, Pharmaceutical Division of VivoMetrics. "I believe that the LifeShirt System is a completely novel way of collecting clinical data that complements Perceptive’s expertise in implementing technologies that help reduce the time and costs associated with the clinical trial process."
About Perceptive Informatics, Inc.
Perceptive Informatics, Inc. develops and offers a portfolio of sophisticated and innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales. The technology portfolio includes web-based portal solutions and tracking tools, Interactive Voice Response Systems (IVRS), and clinical trial management systems (CTMS). IMPACT™ is Perceptive’s market leading CTMS product and Initiator™ is a trial management product targeted to the needs of Phase I units. Perceptive offers advanced medical diagnostics services to assess rapidly and objectively the safety and efficacy of new drugs, biologics, and medical devices in clinical trials. The company also provides electronic data capture, electronic diary, and investigator database solutions. Perceptive is headquartered near Boston, MA with approximately 260 employees in offices located throughout North America and Europe. Perceptive Informatics is a subsidiary of PAREXEL International Corporation, one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. PAREXEL operates in 57 locations throughout 36 countries around the world, and has approximately 5,100 employees.
VivoMetrics is a privately held company that provides continuous ambulatory monitoring products and services for the collection, analysis and reporting of patient-specific physiologic data. The company’s offerings, based on proprietary, field-tested technologies improve the process and economics of pharmaceutical clinical trials and allow for the collection of high-resolution physiologic data in “real-world” environments.
This release contains "forward-looking" statements that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", “estimates”, “projects” and similar expressions are intended to identify forward-looking statements. PAREXEL's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts; PAREXEL's dependence on certain industries and clients; PAREXEL's ability to win new business, manage growth, and attract and retain employees; PAREXEL's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry; competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of PAREXEL's Amendment No. 1 to Registration Statement on Form S-3/A, as filed with the Securities and Exchange Commission on May 22, 2003, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent PAREXEL’s estimates as of the date of this release. PAREXEL specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing PAREXEL’s estimates or views as of any date subsequent to the date of this press release.
*LifeShirt and VivoLogic are trademarks of VivoMetrics, Inc.